Avarol inhibits TNF-α generation and NF-κB activation in human cells and in animal models

Life Sciences

Volumn 82, Issue 5-6, 2008, Pages 256-264

  Amigó, Maria ^a   Payá, Miguel ^a   Braza Boïls, Aitana ^a   De Rosa, Salvatore ^b   Terencio, Maria Carmen ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Avarol; IL 1 ; Keratinocyte; Mouse skin; NF B; Psoriasis; TNF

Indexed keywords

AVAROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2; LEUKOTRIENE B4; MYELOPEROXIDASE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL CULTURE; CONTROLLED STUDY; DISEASE COURSE; DNA BINDING; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVITY; EPIDERMIS HYPERPLASIA; FEMALE; GEL MOBILITY SHIFT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KERATINOCYTE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN FUNCTION; PSORIASIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMIS; FEMALE; HUMANS; HYPERPLASIA; INFLAMMATION; INFLAMMATION MEDIATORS; KERATINOCYTES; MICE; MONOCYTES; NF-KAPPA B P50 SUBUNIT; PEROXIDASE; PSORIASIS; SESQUITERPENES; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 38349059615     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.11.017     Document Type: Article

References (47)

1. Afaq F., Saleem M., Krueger C.G., Reed J.D., and Mukhtar H. Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice. International Journal of Cancer 113 3 (2005) 423-433
2. Amigó M., Payá M., De Rosa S., and Terencio M.C. Antipsoriatic effects of avarol-3'-thiosalicylate are mediated by inhibition of TNF-alpha generation and NF-kappaB activation in mouse skin. British Journal of Pharmacology 152 3 (2007) 353-365
3. Amigó M., Schalkwijk J., Olthuis D., De Rosa S., Payá M., Terencio M.C., and Lamme E. Identification of avarol derivatives as potential antipsoriatic drugs using an in vitro model for keratinocyte growth and differentiation. Life Sciences 79 25 (2006) 2395-2404
4. Amigó M., Terencio M.C., Mitova M., Iodice C., Payá M., and De Rosa S. Potential antipsoriatic avarol derivatives as antioxidants and inhibitors of PGE(2) generation and proliferation in the HaCaT cell line. Journal of Natural Products 67 9 (2004) 1459-1463
5. Asadullah K., Volk H.D., and Sterry W. Novel immunotherapies for psoriasis. Trends in Immunology 23 1 (2002) 47-53
6. Banno T., Gazel A., and Blumenberg M. Effects of tumor necrosis factor-alpha (TNF alpha) in epidermal keratinocytes revealed using global transcriptional profiling. The Journal of Biological Chemistry 279 31 (2004) 32633-32642
7. Banno T., Gazel A., and Blumenberg M. Pathway-specific profiling identifies the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in epidermal keratinocytes. The Journal of Biological Chemistry 280 19 (2005) 18973-18980
8. Bayliffe A.I., Brigandi R.A., Wilkins H.J., and Levick M.P. Emerging therapeutic targets in psoriasis. Current Opinion in Pharmacology 4 3 (2004) 306-310
9. Belisario M.A., Maturo M., Pecce R., De Rosa S., and Villani G.R. Effect of avarol and avarone on in vitro-induced microsomal lipid peroxidation. Toxicology 72 2 (1992) 221-233
10. Borenfreund E., Babick H., and Martin-Alguacil N. Comparison of two in vitro cytotoxicity assays. The natural (NR) and tetrazolium (MTT) test. Toxicology 2 (1988) 1-6 (In Vitro)
11. Bos J.D., de Rie M.A., Teunissen M.B., and Piskin G. Psoriasis: dysregulation of innate immunity. British Journal of Dermatology 152 6 (2005) 1098-1107
12. Boukamp P., Petrussevska R.T., Breitkreutz D., Hornung J., Markham A., and Fusenig N.E. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. The Journal of Cell Biology 106 3 (1988) 761-771
13. Briganti S., and Picardo M. Antioxidant activity, lipid peroxidation and skin diseases. What's new. Journal of the European Academy of Dermatology and Venereology 17 6 (2003) 663-669
14. Bustos G., Ferrándiz M.L., Sanz M.J., Payá M., and Alcaraz M.J. A study of the novel anti-inflammatory agent florifenine topical anti-inflammatory activity and influence on arachidonic acid metabolism and neutrophil functions. Naunyn-Schmiedeberg's Archives of Pharmacology 351 3 (1995) 298-304
15. De Rosa S. In: Rauter A.P. (Ed). Mediterranean Marine Organisms as Source of New Potential Drugs. Natural Products in the New Millennium: Prospects and Industrial Application (2002), Kluwer Academic Press, Dordrecht 441-461
16. Ferrándiz M.L., Sanz M.J., Bustos G., Payá M., Alcaraz M.J., and De Rosa S. Avarol and avarone, two new anti-inflammatory agents of marine origin. European Journal of Pharmacology 253 1-2 (1994) 75-82
17. Gaspari A.A. Innate and adaptive immunity and the pathophysiology of psoriasis. Journal of the American Academy of Dermatology 54 3 Suppl 2 (2006) S67-S80
18. Goffe B., and Cather J.C. Etanercept: an overview. Journal of the American Academy of Dermatology 49 2 Suppl (2003) S105-S111
19. Gottlieb A.B. Therapeutic options in the treatment of psoriasis and atopic dermatitis. Journal of the American Academy of Dermatology 53 1 Suppl 1 (2005) S3-S16
20. Han S.S., Keum Y.S., Seo H.J., Chun K.S., Lee S.S., and Surh Y.J. Capsaicin suppresses phorbol ester-induced activation of NF-kappaB/Rel and AP-1 transcription factors in mouse epidermis. Cancer Letters 164 2 (2001) 119-126
21. Johansen C., Flindt E., Kragballe K., Henningsen J., Westergaard M., Kristiansen K., and Iversen L. Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. Journal of Investigative Dermatology 124 6 (2005) 1284-1292
22. Kohler H.B., Huchzermeyer B., Martin M., De Bruin A., Meier B., and Nolte I. TNF-alpha dependent NF-kappa B activation in cultured canine keratinocytes is partly mediated by reactive oxygen species. Veterinary Dermatology 12 3 (2001) 129-137
23. Lan C.C., Yu H.S., Wu C.S., Kuo H.Y., Chai C.Y., and Chen G.S. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappaB. British Journal of Dermatology 153 4 (2005) 725-732
24. Lizzul P.F., Aphale A., Malaviya R., Sun Y., Masud S., Dombrovskiy V., and Gottlieb A.B. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. Journal of Investigative Dermatology 124 6 (2005) 1275-1283
25. Mendonca C.O., and Burden A.D. Current concepts in psoriasis and its treatment. Pharmacology and Therapeutics 99 2 (2003) 133-147
26. Minale L., Riccio R., and Sodano G. Avarol a novel sesquiterpenoid hydroquinone with a rearranged drimane skeleton from the sponge Disidea avara. Tetrahedron Letters 15 (1974) 3401-3404
27. Moriyama H., Tsukida T., Inoue Y., Yokota K., Yoshino K., Kondo H., Miura N., and Nishimura S. Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. Journal of Medicinal Chemistry 47 8 (2004) 1930-1938
28. Moustafa M., Szabo M., Ghanem G.E., Morandini R., Kemp E.H., MacNeil S., and Haycock J.W. Inhibition of tumor necrosis factor-alpha stimulated NFkappaB/p65 in human keratinocytes by alpha-melanocyte stimulating hormone and adrenocorticotropic hormone peptides. Journal of Investigative Dermatology 119 6 (2002) 1244-1253
29. Mrowietz U., and Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends in Molecular Medicine 11 1 (2005) 43-48
30. Murakawa M., Yamaoka K., Tanaka Y., and Fukuda Y. Involvement of tumor necrosis factor (TNF)-alpha in phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin edema in mice. Biochemical Pharmacology 71 9 (2006) 1331-1336
31. Norris D.A. Mechanisms of action of topical therapies and the rationale for combination therapy. Journal of the American Academy of Dermatology 53 1 Suppl 1 (2005) S17-S25
32. Oberyszyn T.M., Tober K.L., Ross M.S., and Robertson F.M. Inhibitory effects of pentoxifylline on ultraviolet B light-induced cutaneous inflammation. Molecular Carcinogenesis 22 1 (1998) 16-25
33. Okayama Y. Oxidative stress in allergic and inflammatory skin diseases. Current drug targets. Inflammation and Allergy 4 4 (2005) 517-519
34. Pennanen N., Lapinjoki S., Palander A., Urtti A., and Monkkonen J. Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretion. International Journal of Immunopharmacology 17 6 (1995) 475-480
35. Pfundt R., Wingens M., Bergers M., Zweers M., Frenken M., and Schalkwijk J. TNF-alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. Archives of Dermatological Research 292 4 (2000) 180-187
36. Pittelkow M.R. Psoriasis: more than skin deep. Nature Medicine 11 1 (2005) 17-18
37. Posadas I., Terencio M.C., Guillen I., Ferrándiz M.L., Coloma J., Payá M., and Alcaraz M.J. Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn-Schmiedeberg's Archives of Pharmacology 361 1 (2000) 98-106
38. Reynolds N.J., McCombie S.W., Shankar B.B., Bishop W.R., and Fisher G.J. SCH 47112, a novel staurosporine derivative, inhibits 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and epidermal hyperplasia in hairless mouse skin. Archives of Dermatological Research 289 9 (1997) 540-546
39. Rioja I., Terencio M.C., Ubeda A., Molina P., Tarraga A., Gonzalez-Tejero A., and Alcaraz M.J. A pyrroloquinazoline derivative with anti-inflammatory and analgesic activity by dual inhibition of cyclo-oxygenase-2 and 5-lipoxygenase. European Journal of Pharmacology 434 3 (2002) 177-185
40. Sato H., Nakayama Y., Yamashita C., and Uno H. Anti-inflammatory effects of tacalcitol (1,24(R)(OH)2D3, TV-02) in the skin of TPA-treated hairless mice. Journal of Dermatology 31 3 (2004) 200-217
41. Sawa M., Tsukamoto T., Kiyoi T., Kurokawa K., Nakajima F., Nakada Y., Yokota K., Inoue Y., Kondo H., and Yoshino K. New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs. Journal of Medicinal Chemistry 45 4 (2002) 930-936
42. Schottelius A.J., Moldawer L.L., Dinarello C.A., Asadullah K., Sterry W., and Edwards III C.K. Biology of tumor necrosis factor-alpha-implications for psoriasis. Experimental Dermatology 13 4 (2004) 193-222
43. Sipkema D., Osinga R., Schatton W., Mendola D., Tramper J., and Wijffels R.H. Large-scale production of pharmaceuticals by marine sponges: sea, cell, or synthesis?. Biotechnology and Bioengineering 90 2 (2005) 201-222
44. Tak P.P., and Firestein G.S. NF-kappaB: a key role in inflammatory diseases. Journal of Clinical Investigation 107 1 (2001) 7-11
45. 4 and tumour necrosis factor alpha release in acute inflammatory responses by novel prenylated hydroquinone derivatives. Naunyn-Schmiedeberg's Archives of Pharmacology 357 5 (1998) 565-572
46. Umezawa K., and Chaicharoenpong C. Molecular design and biological activities of NF-kappaB inhibitors. Molecules and Cells 14 2 (2002) 163-167
47. Yildirim M., Inaloz H.S., Baysal V., and Delibas N. The role of oxidants and antioxidants in psoriasis. Journal of the European Academy of Dermatology and Venereology 17 1 (2003) 34-36